Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
- Revenue in USD (TTM)8.30m
- Net income in USD-46.96m
- Incorporated2014
- Employees53.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citius Pharmaceuticals Inc | 0.00 | -39.77m | 70.19m | 22.00 | -- | 0.8192 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Connect Biopharma Holdings Ltd (ADR) | 24.12m | -21.25m | 70.73m | 81.00 | -- | 0.6402 | -- | 2.93 | -0.3869 | -0.3869 | 0.436 | 2.00 | 0.1826 | -- | -- | 297,728.40 | -16.09 | -66.24 | -17.73 | -71.36 | -- | -- | -88.10 | -- | -- | -- | 0.0029 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
Immuneering Corp | 0.00 | -56.07m | 70.87m | 66.00 | -- | 1.07 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
VolitionRX Ltd | 976.52k | -32.42m | 71.18m | 110.00 | -- | -- | -- | 72.89 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 72.69m | 127.00 | -- | 1.36 | -- | 14.54 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
Citius Oncology Inc | 0.00 | 1.93m | 73.44m | -- | 4.26 | 0.1486 | 37.98 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
Cue Biopharma Inc | 8.30m | -46.96m | 74.06m | 53.00 | -- | 2.77 | -- | 8.93 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
Aileron Therapeutics Inc | 0.00 | -25.22m | 74.53m | 15.00 | -- | 1.33 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Metagenomi Inc | 55.93m | -75.00m | 75.30m | 228.00 | -- | 0.2795 | -- | 1.35 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
Cidara Therapeutics Inc | 31.58m | -116.17m | 75.38m | 69.00 | -- | 0.3737 | -- | 2.39 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
IO Biotech Inc | 0.00 | -88.00m | 75.76m | 68.00 | -- | 0.787 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
PMV Pharmaceuticals Inc | 0.00 | -48.88m | 76.51m | 63.00 | -- | 0.357 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Chimerix Inc | 144.00k | -84.70m | 77.54m | 72.00 | -- | 0.4983 | -- | 538.45 | -0.9507 | -0.9507 | 0.0016 | 1.74 | 0.0007 | -- | 1.86 | 2,000.00 | -40.37 | -30.45 | -44.33 | -34.09 | 10.42 | -- | -58,820.14 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
Ovid Therapeutics Inc | 567.53k | -29.75m | 78.07m | 40.00 | -- | 0.8781 | -- | 137.56 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Sellas Life Sciences Group Inc | 0.00 | -34.44m | 78.49m | 16.00 | -- | 24.19 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Bleichroeder LPas of 31 Mar 2024 | 2.76m | 5.66% |
Slate Path Capital LPas of 31 Mar 2024 | 2.40m | 4.94% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.21m | 4.55% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.08m | 4.27% |
Park City Capital LLCas of 05 Jun 2024 | 1.00m | 2.06% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 759.80k | 1.56% |
Geode Capital Management LLCas of 30 Jun 2024 | 492.46k | 1.01% |
Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Mar 2024 | 478.50k | 0.98% |
Millennium Management LLCas of 31 Mar 2024 | 362.09k | 0.74% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 345.32k | 0.71% |